Baird lowered the firm’s price target on Bio-Techne to $68 from $90 and keeps an Outperform rating on the shares. The firm said they reported a 1Q revenue/EPS miss and lowered expectations for 2024 organic growt and like other peers, incremental China pressures and cautious pharma/biotech spending weighed on growth.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TECH:
